Todays Market Leaders for Investor (KERX, BOX, GALT, RIMM)

Los Angelas, CA -- (SBWIRE) -- 01/23/2013 -- Keryx (NASDAQ:KERX) announced that its Japanese partner, Japan Tobacco, has filed its New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare for marketing approval of Zerenex in Japan. Zerenex is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). Efficacy and safety data from several successfully completed Phase 3 studies in CKD patients with hyperphosphatemia in Japan has provided ample support for the filing. Keryx will receive a non-refundable payment of $7 million for the achievement of the NDA filing milestone under the license agreement. Ron Bentsur, Chief Executive Officer of Keryx, said that the company eagerly awaits top-line results from its U.S. long-term Phase 3 study in dialysis patients, and U.S. NDA and European MAA filings will follow suit.

How To Trade KERX After The Recent Momentum? Find Out Here

Shares of SeaCube Container Leasing (NYSE:BOX) jumped 13.5% today after the company announced a buyout. The Ontario Teachers' Pension Plan is buying SeaCube for $467 million, and shareholders will receive $23 per share. The deal has been approved by SeaCube's board and is expected to close early this year. Shares are now trading above the $23 buyout price, indicating investors are expecting a higher bid. That's a risky bet, and the stock is well over its 52-week high, so cashing in here is what I would be doing. If you can get more than the buyout offer without risking that the deal will fall through orthat another buyer doesn't come through, it's the right financial move.

Can BOX Continue To Move Higher? Find Out Here

Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse the primary kidney disease associated with diabetes, called diabetic nephropathy, the leading cause of kidney failure, dialysis and kidney transplant. GR-MD-02 is the Company’s lead galectin inhibitor in development for the treatment of liver fibrosis, including non-alcoholic steatohepatitis (NASH) liver disease.

Is GALT A Buy The recent High Volatility? Find Out Here

Research In Motion (NASDAQ:RIMM) has released a new system to allow its biggest customers to use its new line of BlackBerry 10 smartphones on their own networks, paving the way for the January 30 launch of the make-or-break devices.RIM said on Wednesday that the new device management system - BlackBerry Enterprise Service 10 (BES 10)- is now available to government agencies and corporate clients. The system lets clients support both corporate-and employee-owned devices and provides a single platform to manage BlackBerry, Android and Apple's iOS-based devices.The Blackberry smartphones, powered by an all-new operating system, are pivotal to the future of RIM, which has ceded market share to Apple Inc's iPhone and devices powered by Google Inc's market-leading Android operating system.

Should Investor Book Profit and Exit From RIMM: Need Instant Reply Check Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com